Keyword: University of Maryland

breast cancer

PARP inhibitor plus epigenetic inhibitor reduces cancer growth and survival

Poly(ADP-ribose) polymerase inhibitors (PARPis) are an exciting class of cancer drugs currently used in the clinic. To date, however, patients with acute myeloid leukemia--a cancer with a notoriously poor outcome after diagnosis--have failed to respond to them. Scientists have recently shown that combining PARPis with an epigenetic modifier significantly reduces cancer growth and survival of leukemia cells.